Emcure Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,820 Cr +24.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
EP

Emcure Pharmaceuticals Ltd

Q1 FY27

Emcure Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,580Cr
+22.8% YoY
+4.5% QoQ
Net profit
₹292Cr
+35.8% YoY
+19.7% QoQ
Margin
21%
+1 pp YoY
+2 pp QoQ

What the Q1 FY27 call signalled

3 of 4 strong

RevenueModerate growth
MarginMargins slightly up
CapexCapex planned
Order bookOrder book rising
Price₹1,821
Market cap₹34.5K Cr
P/E33.5

The short version

Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.

From Emcure Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter.
  • Domestic business growth is anticipated to improve from current levels, targeting to be in line with or faster than industry growth from Q2 onward.
  • Organic domestic growth guided at 6%-8%, with acceleration expected in the second half of FY27.
  • International business, especially Europe, Canada, and Rest of World markets, poised for solid growth supported by new launches, strong approval pipeline, and differentiated products.
  • ARV and non-ARV segments in international markets expected to contribute roughly equally (~50:50) over the full year.
  • R&D expenses will increase, maintaining around 4%-5% of revenues to support innovation and growth.

2 more points from Emcure Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.
  • They continue to focus on building differentiated capabilities in biologics, complex injectables, and novel delivery systems, particularly liposomal technology.
  • Recent technology transfer initiatives include licensing a novel anti-HPV candidate from ICMR, part of women's health R&D pipeline.
  • Entered a royalty-free licensing agreement with MSD to manufacture a generic oral HIV pill for low and lower-middle income countries, strengthening their ARV portfolio.

2 more points from Emcure Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Emcure is ramping up supplies across different countries, leading to an increase in the order book in line with supplies.
  • The company sees good visibility on some order books, particularly in the ARV (antiretroviral) segment.
  • The Rest of the World business growth is strongly supported by ARV and tender-based products with ongoing procurement cycles expected to pick up in coming quarters.
  • Emcure expects continued momentum from new product launches and bolt-on acquisitions contributing to orderbook buildup.

Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Emcure Pharmaceuticals Ltd Q1 FY27 results — key figures

Emcure Pharmaceuticals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue2,5802,101+22.8%2,470+4.5%
Operating profit (EBITDA)532417+27.6%480+10.8%
Operating margin21%20%+1 pp19%+2 pp
Profit before tax394291+35.4%341+15.5%
Net profit (PAT)292215+35.8%244+19.7%
EPS (₹)15.5010.92+41.9%12.84+20.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹325 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Emcure Pharmaceuticals Ltd Q1 FY27 results?

Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.

What is Emcure Pharmaceuticals Ltd share price analysis?

Emcure Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.5 with a market cap of ₹34,539 Cr. Investors should review the full earnings analysis for detailed insights.

Is Emcure Pharmaceuticals Ltd planning capital expenditure?

The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.

Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.